VIVEbiotech, a lentiviral vector Contract Development and Manufacturing Organization (CDMO), has announced a growth equity investment from Ampersand Capital Partners that will enable the expansion of its lentiviral vector manufacturing capabilities in San Sebastian, Gipuzkoa, Spain and support the execution of a robust pipeline of customer projects for innovators developing groundbreaking in vivo and ex vivo cell and gene therapies.
 
VIVEbiotech provides process development, manufacturing and analytical testing for leading biopharmaceutical companies engaged in gene therapy and cell therapy projects. With a specific focus on lentiviral vector production, the company operates a 3,000 sq. m. (32,000 sq. ft.) GMP-compliant facility in San Sebastián, Gipuzkoa, Spain. VIVEbiotech has a proprietary platform for custom lentiviral vector development and manufacturing, and their highly educated and skilled team of over 140 employees, with more than 85% holding advanced degrees, ensures top-tier expertise and compliance with international standards.
 
Jon Alberdi, CEO of VIVEbiotech, said: “We are thrilled to welcome Ampersand as a key partner to accelerate VIVEbiotech’s ambitious growth plan while strengthening our flexible, plug-and-play platform. This partnership will play an important role in continuing to exceed our customers’ high expectations. The combination of Ampersand’s industry expertise and VIVE’s robust team will position VIVE as a market leader by expanding our capacity and unique capabilities.”
 
Marina Pellon-Consunji, Partner at Ampersand, added, “We are thrilled to support VIVEbiotech in their mission to advance lentiviral vector development. The team’s scientific expertise and innovative approach make them a key player in the rapidly growing cell and gene therapy industry. Through this investment, we look forward to partnering with Jon and his team to solidify VIVE as a global leader in lentiviral vector for in vivo and ex vivo cell and gene therapy.”